News
-
-
-
-
-
-
PRESS RELEASE
Dogwood Announces Enrollment of First 100 Patients in Ongoing Halneuron(R) Phase 2b Trial, Interim Sample Size Analysis on Track for December 2025
Dogwood Therapeutics reports low early termination rate in ongoing HALT-CINP Phase 2b trial for Halneuron® vs placebo in cancer patients with chemotherapy-induced neuropathy. Recruitment on track with 100 patients enrolled for study evaluation -
PRESS RELEASE
EQS-Adhoc: PATRIZIA SE: PATRIZIA raises guidance for EBITDA and EBITDA margin and specifies guidance for assets under management (AUM) for the 2025 financial year
PATRIZIA SE raises EBITDA and EBITDA margin guidance for 2025 financial year. Specifies AUM guidance. Positive financial performance in Q1-Q3 2025 -
PRESS RELEASE
NanoViricides Announces Pricing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close
NanoViricides, Inc. announces securities purchase agreement for $6 million registered direct offering. Proceeds for working capital and corporate purposes -
-
